Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | PYGM | P11217 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404680 | 0.85 | GPR35 (0.42) | GPR35MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL13300574 | 0.81 | ABCG2 (0.52) | GPR35MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7432239 | 0.79 | GPR35 (0.46) | GPR35MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6784145 | 0.76 | TERT (0.61) | NPC1RAB9AMAPT | |
| SCHEMBL6408811 | 0.76 | MEN1 (0.64) | SERPINE1MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL7436468 | 0.76 | NPC1 (0.56) | MEN1KMT2ANPC1RAB9AABCG2 | |
| SCHEMBL6407924 | 0.75 | NPC1 (0.56) | SERPINE1MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL3279060 | 0.75 | HCAR2 (0.47) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL3279047 | 0.75 | HCAR2 (0.47) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL9131506 | 0.74 | GPBAR1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| CN-1048239-C | Naphthalene deriv. | TEIJIN LTD (JP) | 2000-01-12 | — | — | CN | disclosed |
| EP-0763523-B1 | NAPHTHALENE DERIVATIVE | TEIJIN LTD (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-5945450-A | ANTIALLERGENS | TEIJIN LIMITED (JP) | 1999-08-31 | — | — | US | disclosed |
| CN-1153511-A | Naphthalene deriv. | TEIJIN LTD (JP) | 1997-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | GPR35 3306/4885SERPINE1 4734/4885MEN1 3155/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | GPR35 2790/4885SERPINE1 4640/4885MEN1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.